PMV Pharmaceuticals Faces Funding Concerns Despite Positive Clinical Trial Results
Despite positive clinical trial results and an FDA orphan drug designation for its candidate rezatapopt in ovarian cancer treatment, PMV Pharmaceuticals faces potential funding concerns. The company reported $93.5 million in cash as of Q1 2026 but may require additional capital to support operations through the expected mid-to-late 2027 approval timeline.
Tickers: $PMVP
Topics: cash reserves clinical trials funding concerns pharmaceuticals